Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419910 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
A Phase 1 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT03419910 is a Phase 1 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03419910, a Phase 1 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
Conditions Studied
Interventions
- DRUG Cyclosporine
- DRUG BMS-986165
Study Locations (1)
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03419910
The ClinicalTrials.gov registry entry for NCT03419910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (89% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Cyclosporine is the first listed.
NCT03419910 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03419910 about?
NCT03419910 is a clinical study titled "An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants". This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
What is the current status of trial NCT03419910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2018-03-05. Estimated completion is 2018-05-04.
What conditions does trial NCT03419910 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03419910?
The interventions under investigation include: Cyclosporine (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03419910?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03419910 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.